SavedAdd your journal

Journals / Eurasian Journal of Medicine and Oncology / 2019 / Cilt: 3 - Sayı: 2

Understanding Clinical Pharmacogenomics: A Descriptive Review

Jesse RAMEY
Prashanth REDDY
Narendra DATLA
Shiva PRAKASH
Yogesh ACHARYA
Pages
92–100
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We identified 27 drug-biomarker pairs on the highest ratings of confidence based on FDA, CPIC, and PharmGKB and chose 9 exemplary drugs to tabulate the association study (GWAS), PharmGKB dosing and FDA PGx actionability.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Pharmacogenomics (PGx) is the study of the correlation between an individual’s genome and their response to specific medications.
📊
Key Findings & Data:While different individuals respond differently to drugs, it has only been since the documentation of the human genome in 2003 that researchers have been able to make a tighter genetic connection with their metabolism.
💡
Conclusion & Impact:We identified 27 drug-biomarker pairs on the highest ratings of confidence based on FDA, CPIC, and PharmGKB and chose 9 exemplary drugs to tabulate the association study (GWAS), PharmGKB dosing and FDA PGx actionability.
🔬Design:Review & Systematic Survey
📍Scope:2003 Verileri
⚙️Variables:Domain Parameters

Özet

Pharmacogenomics (PGx) is the study of the correlation between an individual’s genome and their response to specific medications. While different individuals respond differently to drugs, it has only been since the documentation of the human genome in 2003 that researchers have been able to make a tighter genetic connection with their metabolism. This study explores the current state of the PGx as of 2019 with an emphasis on its clinical usefulness. We analyzed data from the Food and Drug Administration (FDA), the Clinical Pharmacogenetics Implementation Consortium (CPIC) and PharmGKB, three key organizations that support pharmacogenomics in the US. A supported literature review was performed from PubMed and ClinCalc. We identified 27 drug-biomarker pairs on the highest ratings of confidence based on FDA, CPIC, and PharmGKB and chose 9 exemplary drugs to tabulate the association study (GWAS), PharmGKB dosing and FDA PGx actionability.

🔖

Cite This Article

RAMEY, J., REDDY, P., DATLA, N., PRAKASH, S., ACHARYA, Y. (2019). Understanding Clinical Pharmacogenomics: A Descriptive Review. Eurasian Journal of Medicine and Oncology, Cilt: 3 - Sayı: 2, 92–100. https://ajindex.com/articles/126028

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. What was the Human Genome Project and why has it been important? Genetics Home Reference. July 3, 2018. Available at: https://ghr.nlm.nih.gov/primer/hgp/description. Accessed March 15, 2019. 2. What We Do. FDA. Available at: https://www.fda.gov/AboutFDA/WhatWeDo/default.htm. Accessed March 15, 2019. 3. CPIC. What is CPIC? Available at: https://cpicpgx.org/. Accessed March 15, 2019. 4. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn F, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 2012
  2. 414–7. 5. Genome-Wide Association Studies. National Human Genome Research Institute (NHGRI). 2018. Available at: https://www. genome.gov/20019523/genomewide-association-studiesfact-sheet/. Accessed March 15, 2019. 6. Clinical tools and calculators for medical professionals – ClinCalc. Available from: http://clincalc.com/. Accessed March 15, 2019. 7. About the HGNC. Available from: https://www.genenames. org/about/overview. Accessed March 15, 2019. 8. HLA Nomenclature. Nomenclature for Factors of the HLA System. Available at http://hla.alleles.org/nomenclature/index. html. Accessed March 15, 2019. 9. Single Nucleotide Polymorphisms (SNPs). National Human Genome Research Institute (NHGRI). Available at: https:// www.genome.gov/glossary/index.cfm?id=185. Accessed March 15, 2019. 10. Whalen K, Finkel R, Panavelil TA. Pharmacology. 6th edition. Philadelphia: Wolters Kluwer
  3. Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, et al
  4. Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther 2014
  5. 376–82. 12. Crews KR, Gaedigk A, Dunnenberger HM, Klein TE, Shen DD, Callaghan JT, et al
  6. Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther 2011
  7. 321–6. 13. Johnson JA, Caudle KE, Gong L, Whirl-Carrillo M, Stein CM, Scott SA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for PharmacogeneticsGuided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther 2017
  8. 397–404. 14. Daneshi N, Holliday E, Hancock S, Schneider JJ, Scott RJ, Attia J, et al. Prevalence of clinically actionable genotypes and medication exposure of older adults in the community. Pharmgenomics Pers